High Purity API Idra-21 Powder For Nootropic Supplyment 22503-72-6 Idra21
Place of Origin | CHINA |
---|---|
Brand Name | XRD |
Certification | GMP |
Model Number | 22503-72-6 |
Minimum Order Quantity | negotiable |
Price | Inquiry for Negotiable |
Packaging Details | 1-2 Kg / Aluminum Foil Bag, 25kg/ Drum, as Require |
Delivery Time | 1-2days after payment received |
Payment Terms | T/T, Western Union,Bitcoin |
Supply Ability | 5000kg/year |

Contact me for free samples and coupons.
Whatsapp:0086 18588475571
Wechat: 0086 18588475571
Skype: sales10@aixton.com
If you have any concern, we provide 24-hour online help.
xCas No. | 22503-72-6 | Other Names | AMPAKINE |
---|---|---|---|
Product NamRopivacainee | IDRA 21 | Appearance | White Powder |
Assay | 99% IDRA 21 | Grade | Pharmaceutical Grade |
Storage | Cool Dried Storage | Application | Pharmaceutical Raw Intermediates |
High Light | raw materials for pharma industry,intermediates in pharmaceuticals |
High Purity API Idra-21 Powder for Nootropic Supplyment 22503-72-6 Idra21
IDRA-21
Cas Number 22503-72-6
Name: IDRA-21
Formula: C8H9ClN2O2S
Molecular Weight: 232.68726 g/mol
Synonyms: 7-CHLORO-3-METHYL-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE;7-CHLORO-3-METHYL-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE 1,1-DIOXIDE;7-CHLORO-3-METHYL-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE S,S-DIOXID
Asssy 99%+
Appearance: White crystalline powder
IIDRA-21 is an ampakine drug derived from aniracetam, IDRA-21 shows nootropic effects in animal studies
While more research is needed for this relatively new compound, it has taken the nootropic community by storm.
This means it is able to improve focus and attention as well as promote learning and memory.
In comparison to the benzoylpiperidine derived ampakine drugs, IDRA-21 was more potent than CX-516, but less potent than CX-546.Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX-series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.
Studies conducted to evaluate effects of NSI-189 revealed that 40 to 80 mg daily is effective in treating depression and cognitive symptoms amongst healthy patients.
In these trials, there are no serious adverse events recorded. Generally, NSI-189 is well tolerated and safe for human use.
Function
1.Increases in cognitionIncreased Task Accuracy.
2.Increases in Short Term Memory.
3.Potential Therapeutic Effects On Schizophrenia.
4.Potental Therapeutic Effects On Depression.
5.Neuroprotection.
6.Benefits Against Alp-induced Cognitive Deficit.
Packing: